|
| Press Releases |
|
 |
|
| Tuesday, July 31, 2018 |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA |
| The LENVIMA/KEYTRUDA combination therapy is being jointly developed by Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. as part of the strategic collaboration announced in March 2018. more info >> |
|
| Thursday, July 26, 2018 |
|
|
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 "Recent Developments in Therapeutics" at AAIC 2018 being held in Chicago, Illinois, United States on July 25. more info >> |
|
|
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE inhibitor elenbecestat (development code: E2609) at the AAIC 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. more info >> |
|
| Thursday, July 19, 2018 |
|
|
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that a total of 13 presentations highlighting results from a Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 and a Phase II clinical study (Study 202) will be given at the Alzheimer's Association International Conference (AAIC) 2018, in Chicago. more info >> |
|
| Wednesday, July 18, 2018 |
|
|
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ |
| This study was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and is the largest cardiovascular outcome trial conducted to date for a weight loss medication. more info >> |
|
| Wednesday, July 11, 2018 |
|
|
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018. more info >> |
|
| Tuesday, July 10, 2018 |
|
|
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that the results of the Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 will be presented in an oral session at the Alzheimer's Association International Conference (AAIC) 2018 held in Chicago. more info >> |
|
| Monday, July 9, 2018 |
|
|
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology |
| The 2-week double-blind clinical trial was a placebo-controlled, randomized, double-blind trial with 133 Japanese patients with chronic constipation. more info >> |
|
| Friday, July 6, 2018 |
|
|
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months |
| Eisai Co., Ltd. and Biogen Inc. announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. more info >> |
|
| Wednesday, July 4, 2018 |
|
|
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
African Mining Giant Intends to List in Hong Kong to Build West African Gold Leader
May 13, 2025 22:25 HKT/SGT
|
|
|
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud
May 13, 2025 19:00 HKT/SGT
|
|
|
Widespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research Finds
May 13, 2025 17:05 HKT/SGT
|
|
|
EdgePoint completes 12 projects under its Connectivity for Communities Program, impacting more than 6,500 students across Malaysia, Indonesia and the Philippines 
May 13, 2025 15:00 HKT/SGT
|
|
|
Nissin Foods Announces 2025 Q1 Financial Results
May 13, 2025 12:47 HKT/SGT
|
|
|
Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security
May 13, 2025 11:00 JST
|
|
|
Business Delegation Forges New Collaborations in Qatar
May 12, 2025 22:02 HKT/SGT
|
|
|
Euro Manganese Announces Appointment of Ms. Martina Blahova as Permanent President & Chief Executive Officer
May 12, 2025 20:09 HKT/SGT
|
|
|
TOYOTA GAZOO Racing fights back for double points finish
May 12, 2025 15:45 JST
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 12, 2025 14:00 HKT/SGT
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 12, 2025 13:40 HKT/SGT
|
|
|
Global Crypto Leaders to Converge in Dubai for Historic 30th Edition of HODL
May 12, 2025 13:00 HKT/SGT
|
|
|
Solar & Storage Live Philippines 2025 Powers Up to Drive the Nation's Clean Energy Future
May 12, 2025 12:00 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 12, 2025 10:45 HKT/SGT
|
|
|
JCB and Arab Bank launch JCB merchant acquiring operations across Jordan
May 12, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
